Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC021: Trametinib and Everolimus in Recurrent Gliomas
NCT04485559Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib and everolimus in glioma, sponsored by University of California, San Francisco. Primary endpoints: Maximum Tolerated Dose at 28 days, Incidence of Adverse Events and 4 more. Started Dec 2020; status: recruiting.
02
Drugs
trametinibeverolimus
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04485559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485559.